AstraZeneca plc (LON:AZN) declared a dividend on Friday, February 2nd, Upcoming.Co.Uk reports. Shareholders of record on Thursday, February 15th will be paid a dividend of GBX 133.60 ($1.85) per share by the biopharmaceutical company on Monday, March 19th. This represents a yield of 2.8%. The ex-dividend date of this dividend is Thursday, February 15th. This is a boost from AstraZeneca’s previous dividend of $68.90. The official announcement can be seen at this link.
AstraZeneca (LON AZN) traded up GBX 23.50 ($0.32) during mid-day trading on Wednesday, hitting GBX 4,854 ($67.06). 912,200 shares of the company’s stock traded hands, compared to its average volume of 2,070,000. The stock has a market capitalization of $60,820.00 and a price-to-earnings ratio of 2,838.60. AstraZeneca has a 1-year low of GBX 4,260 ($58.86) and a 1-year high of GBX 5,520 ($76.26).
Several analysts have commented on the stock. Investec increased their price target on shares of AstraZeneca from GBX 4,900 ($67.70) to GBX 5,500 ($75.99) and gave the company a “buy” rating in a research report on Monday, November 6th. Jefferies Group reissued a “hold” rating and set a GBX 5,100 ($70.46) price target on shares of AstraZeneca in a research report on Monday, November 6th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of AstraZeneca in a research report on Friday, November 10th. Barclays reissued a “top pick” rating and set a GBX 6,300 ($87.04) price target on shares of AstraZeneca in a research report on Monday, February 5th. Finally, Goldman Sachs Group set a GBX 3,800 ($52.50) price target on shares of AstraZeneca and gave the company a “sell” rating in a research report on Monday, February 5th. Four equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of GBX 5,211.65 ($72.00).
In other AstraZeneca news, insider Philip A. J. Broadley bought 415 shares of the stock in a transaction on Friday, February 2nd. The shares were bought at an average price of GBX 4,846 ($66.95) per share, with a total value of £20,110.90 ($27,785.16).
COPYRIGHT VIOLATION WARNING: This story was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://www.dispatchtribunal.com/2018/02/14/astrazeneca-plc-azn-to-go-ex-dividend-on-february-15th.html.
AstraZeneca Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.